Business context and reporting period
Stryker Corporation is a global medical technology company operating in Orthopaedics, MedSurg, and Neurotechnology and Spine. This Form 10-K covers the fiscal year ended December 31, 2020; the filing also reports unaudited fourth-quarter results. Dollar amounts below are in millions except per-share data.
Financial performance and liquidity
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Net sales | $14,351 | $14,884 |
| Gross profit / margin | $9,057 / 63.1% | $9,696 / 65.1% |
| Operating income / margin | $2,223 / 15.5% | $2,713 / 18.2% |
| Net earnings | $1,599 | $2,083 |
| Diluted EPS | $4.20 | $5.48 |
| Adjusted diluted EPS (non-GAAP) | $7.43 | $8.26 |
| Cash from operating activities | $3,277 | $2,191 |
| Free cash flow (non-GAAP) | $2,821 | $1,622 |
FY 2020 sales declined 3.6% as reported and in constant currency. Adjusted net earnings were $2,827, down from $3,139 in 2019; management reported adjusted EPS down 10.0%. Fourth-quarter sales were $4,262 versus $4,131, while net earnings were $568 versus $725 and diluted EPS was $1.49 versus $1.90.
At year-end, cash, cash equivalents and current marketable securities totaled $3,024, and current assets exceeded current liabilities by $4,666. Total debt was $13,991, up from $11,090; shareholders’ equity was $13,084. The company reported $3,292 of debt issuance and $2,297 of debt repayments during 2020. Dividends paid totaled $863; no shares were repurchased.
Material changes versus the prior comparable period
- COVID-19-related postponements of elective procedures reduced demand, particularly for knee and hip implants, endoscopy, instruments, spine, and neurotechnology products. Medical products benefited from higher demand.
- Orthopaedics sales fell 5.6%, MedSurg fell 1.4%, and Neurotechnology and Spine fell 4.7%. Medical product sales rose 11.5%, while knee and hip sales fell 13.7% and 12.8%, respectively.
- Gross and operating margins contracted amid lower sales and manufacturing volumes, lower selling prices, and unfavorable product mix. Stryker also recorded $195 of asset impairments and exit costs, primarily related to suspending in-process investments in a new global ERP system.
- Acquisitions used $4,222 of net cash. Stryker completed its Wright Medical acquisition in November and acquired OrthoSensor in December. Debt increased, while cash and current marketable securities decreased from $4,425 to $3,024.
- Operating cash flow improved, partly due to working-capital movements, including higher receivable collections and lower inventory spending; it was not solely attributable to earnings growth.
Outlook, commentary, risks and unusual items
Management’s stated long-term goal is sales growth at the high end of the MedTech industry. The filing provides no specific numerical FY 2021 revenue or earnings guidance. Management said liquidity and operating needs could be supported by operating cash flow, commercial paper, credit lines, and expense or capital-spending reductions. Share repurchases were suspended through 2021; capital allocation priorities were acquisitions, dividends, then share repurchases.
The company cautioned that pandemic effects remained difficult to predict, including renewed elective-procedure delays, supply-chain or distribution disruption, and shifts in demand. Other material risks include medical-device regulation (including EU MDR requirements effective May 2021), pricing pressure, foreign-exchange exposure, acquisition integration, cybersecurity and ERP implementation, and product-liability claims.
Product-liability reserves covered Rejuvenate and ABG II hip stems, LFIT femoral heads, and Wright legacy hip products. The estimated remaining probable-loss range was $470–$720, with reserves recorded at the minimum; ultimate costs could differ materially. Other notable exposures include $457 of uncertain tax positions and underfunded defined-benefit pension plans of $596. The company amended its credit-facility leverage covenant and exercised an acquisition provision permitting maximum leverage of 5.0:1 at December 31, 2020. Its $1.5 billion revolving facility maturing in April 2021 was also disclosed.
Reported results include acquisition, amortization, restructuring, regulatory, recall, legal, and tax items. Adjusted earnings and free cash flow are non-GAAP measures; the filing cautions that they are not standardized or substitutes for GAAP results. The auditor issued unqualified opinions on the financial statements and internal control; Wright was excluded from management’s and the auditor’s internal-control assessment.
Important facts for investors to verify
- Whether elective-procedure volumes recover sustainably and how that affects implant demand, margins, and the quarterly sales trend.
- Wright integration progress, realization of expected benefits, and final purchase-price allocations, which were preliminary for certain acquired assets and liabilities.
- Debt maturities, refinancing plans, covenant headroom, and the effect of the increased leverage allowance on financial flexibility.
- Developments in product-liability claims and whether the $470–$720 estimated loss range and recorded reserves remain adequate.
- The composition and repeatability of adjusted earnings and free cash flow, including working-capital effects and excluded charges.
- Progress on EU MDR compliance and the replacement ERP system, including any further delays, impairments, or operating disruption.